'CSI' technology holds potential in everyday medicineAugust 21, 2012
The report on technology already incorporated into instruments that miniaturize room-size lab instrumentation into devices the size of a shoebox was part of the 244th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society. The meeting, which features about 8,600 reports with an anticipated attendance of 14,000 scientists and others continues here through Thursday.
"With both of the instruments we developed, no sample preparation is needed, which reduces analysis time from as much as several hours per sample to just a few seconds," said Graham Cooks, Ph.D., who led the research team. "Rapid results are critical when a surgeon is operating on a brain tumor or when chemotherapy patients are being treated with powerful drugs that must be administered at precise levels."
The instrument called a "desorption electrospray ionization" mass spectrometer, or DESI, was featured on both CSI and CSI: Miami as a tool to analyze fingerprints. However, this portable instrument can do so much more. It's about the size of a shoebox and does not change or destroy the sample that is analyzed. Cooks' students have even carried it into a grocery store and held it close to the outer surfaces of fruit and vegetables to detect pesticides and microorganisms. The team also used it to identify biomarkers for prostate cancer and to detect melamine, a potentially toxic substance that showed up in infant formulas in China in 2008 and in pet food in the U.S. in 2007. In addition, DESI can detect explosives on luggage.
Now, Cooks' team at Purdue University is teaming up with collaborators led by Nathalie Y. R. Agar, Ph.D., at Harvard University to test the instrument in the operating room during brain cancer surgery, comparing it with the gold standard - traditional analysis of tissue samples by pathologists.
"These procedures are among the longest of all surgical operations, and this new technology offers the promise of reducing the time patients are under anesthesia," Cooks explained. "DESI can analyze tissue samples and help determine the type of brain cancer, the stage and the concentration of tumor cells. It also can help surgeons identify the margins of the tumor to assure that they remove as much of the tumor as possible. These are early days, but the analysis looks promising."
The other instrument under development in Cooks' lab is a "PaperSpray ionization" mass spectrometer. The researchers are using this new device to monitor the levels of chemotherapy drugs in patients' blood in real time. "Many cancer drugs have relatively narrow therapeutic ranges, so they need to be in the blood at certain levels to work properly," he noted. "But at present, that information is not obtained in real time, so a patient could end up with too little or too much of the drug in his or her body."
For a video of PaperSpray, click here: http://www.youtube.com/watch?v=BHcMbFyHxTc
Both the DESI and PaperSpray mass spectrometers work in a similar way. To weigh chemicals, mass spectrometers need to ionize, or give a positive or negative charge to a substance. Mass spectrometers usually do this inside the instrument under a vacuum without air. But DESI and PaperSpray can do this so-called ionization process out in the open. This allows scientists much more flexibility. DESI and PaperSpray also can do analyses without separating out all of the chemicals in a sample first (unlike conventional instruments), which provides quick results. They are also very easy to operate. "You just point and shoot," said Cooks.
Currently, Cooks' team is testing to see whether DESI can provide different information compared to what pathologists can provide by looking at human tissues under a microscope. In addition, the researchers are testing PaperSpray on patients' blood samples, though Cooks points out that the device also could measure the levels of drugs of abuse or pharmaceuticals in urine or other body fluids.
American Chemical Society
Related Chemotherapy Current Events and Chemotherapy News Articles
Surgery on melanoma that has spread into abdomen more than doubles patient survival time
Patients with metastatic melanoma who undergo surgery to remove lesions that have spread into the abdomen live more than twice as long as those treated with drug therapy alone, according to novel new research by a North Shore-LIJ Health System cancer surgeon.
Two-hit therapy for breast tumors using approved drugs looks promising in animal study
Disabling a cancer-causing pathway and administering an immune-molecule-based mop-up therapy eradicated a specific type of breast tumor in mice, according to researchers in the Perelman School of Medicine at the University of Pennsylvania. They describe their findings in Cell Reports.
Targeted chemotherapy shows early signs of slowing tumor growth with less toxicity
Surviving neuroblastoma as a child can come with just as many challenges as the cancer itself, mainly because of the toxic effects of chemotherapy.
Ceritinib in advanced lung cancer: No hint of added benefit
The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC).
Studies suggest new ways to inhibit oncogenes, enhance tumor-suppressor activity
Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes. The findings were reported in the journals Nature Communications and Nature Genetics.
Gene therapy doubles survival in recurrent glioblastoma
An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared to the current standard of care, a researcher said Oct. 1 at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio.
Doctors often overtreat with radiation in late-stage lung cancer
Almost half of patients with advanced lung cancer receive more than the recommended number of radiation treatments to reduce their pain, according to a new study published in the Journal of the National Cancer Institute.
Intratumor morphological heterogeneity of cancer is not related to chromosome aberrations
Intratumor morphological heterogeneity (diversity) of breast cancer is not related to chromosome aberrations. This conclusion was made based on the study of one case with aggressive variant of breast cancer - invasive micropapillary carcinoma by researchers from Tomsk State University (TSU), Tomsk Cancer Research Institute (TCRI), and Institute of Medical Genetics.
First 'targeted' treatment for small cell lung cancer shows promise
Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently only diagnosed when it has spread to other parts of the body (metastasised).
Cancer diagnosis while pregnant should not lead to treatment delay or end of pregnancy
Women who are pregnant when diagnosed with cancer can start treatment for their disease immediately and do not need to terminate their pregnancy due to worries over the effects of therapy on the development of their child.
More Chemotherapy Current Events and Chemotherapy News Articles